Snowball logo
logo
8T8

TRANSMEDICS GROUP

€62.56-€0.14  (0.22%)
Estimate
P/E
18.9
EPS
3.31
Beta
1.926
Growth
Revenue, YoY
23.93%
Net income, YoY
-56.82%
FCF, YoY
-87.29%
About the company
Ticker
8T8
ISIN
US89377M1099
Country
United States of America
Sector (GICS)
Other
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Frequently asked questions

What sector does TRANSMEDICS GROUP (8T8) operate in?

TRANSMEDICS GROUP belongs to the Other sector and operates in the Medical Devices industry.

What is TRANSMEDICS GROUP (8T8) current stock price?

As of the latest data, TRANSMEDICS GROUP stock price is €62.56, with a previous close of €62.70. TRANSMEDICS GROUP lost -€0.14 in the last trading session, representing a -0.22% loss.

What is TRANSMEDICS GROUP (8T8) current market capitalization?

TRANSMEDICS GROUP market cap is approximately 2.17 billion.

What is TRANSMEDICS GROUP (8T8) Earnings Per Share (EPS)?

The trailing EPS is €3.31.

What is TRANSMEDICS GROUP (8T8) Price-to-Earnings (P/E) ratio?

TRANSMEDICS GROUP current P/E ratio is 18.9.

What is TRANSMEDICS GROUP (8T8) EBITDA?

TRANSMEDICS GROUP EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 32.28 million.

Does TRANSMEDICS GROUP (8T8) pay dividends?

No. TRANSMEDICS GROUP does not pay a dividend.

When is TRANSMEDICS GROUP (8T8) next earnings report?

TRANSMEDICS GROUP is expected to release its next earnings report on September 30, 2026.

What is TRANSMEDICS GROUP (8T8) beta (volatility) score?

TRANSMEDICS GROUP has a beta of 1.926, suggesting it is more volatile than the market.